The document provides a market analysis for an analytics company called AlphaMD to enter the pharmaceutical market in the UAE. It includes a literature review on the pharmaceutical sector in UAE, identifying key parameters and needs of target companies through interviews. Based on a decision matrix, marketing pharmaceutical companies were identified as the top target. Recommendations include providing competitive intelligence and contracting services at affordable prices while maintaining quality. Limitations include lack of financial data from SMEs and limited interviews.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Benchmarking Quality: How Medical Device and Diagnostics Companies Manage Cos...Best Practices
Medical device and diagnostics companies spend millions to ensure their products meet quality standards at every stage of the product lifecycle, from R&D to post-market activity. Facing tight budgets and escalating regulations, quality leaders are preparing to shift resources, automate and outsource activities, develop and retain key talent, and build business plans that justify their budgets.
This Best Practices, LLC, report delivers comprehensive survey benchmarks on how medical device companies are defining and allocating Quality spend, identifying factors that impact spending levels, and investing in future mission-critical Quality activities.
Quality leaders can use the evidence-based metrics and insights for Quality spending, staffing, change request levels, outsourcing, software quality, inspections, lab testing, complaint management, trend insights and more.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Benchmarking Quality: How Medical Device and Diagnostics Companies Manage Cos...Best Practices
Medical device and diagnostics companies spend millions to ensure their products meet quality standards at every stage of the product lifecycle, from R&D to post-market activity. Facing tight budgets and escalating regulations, quality leaders are preparing to shift resources, automate and outsource activities, develop and retain key talent, and build business plans that justify their budgets.
This Best Practices, LLC, report delivers comprehensive survey benchmarks on how medical device companies are defining and allocating Quality spend, identifying factors that impact spending levels, and investing in future mission-critical Quality activities.
Quality leaders can use the evidence-based metrics and insights for Quality spending, staffing, change request levels, outsourcing, software quality, inspections, lab testing, complaint management, trend insights and more.
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
Information Management In Pharmaceutical IndustryFrank Wang
Pharmaceutical Industry Information Management Opportunities and Challenges in Research, Development, Clinical, Sales, Marketing, Managed Markets, Manufacturing, Supply Chain and Distribution
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
Health Policy Supporting Innovation in Korean Medical Device Sector (July 11,...Sung Yoon Bae
Presented in the AMCHAM Healthcare Innovation Seminar, held in Seoul, Korea on July 11, 2012.
Title: Toward Better Health Policy Supporting Innovation in Korean Medical Device Sector
Date: July 11, 2012
Speaker, Sung Yoon Bae, Professor of Healthcare Management, Inje University, Busan, Korea
Global supply chain in ranbaxy paonta sahib manufacturing facilityAnkur Srivastava
This is a project report made by me on the Global Supply Chain Process of Ranbaxy Laboratories Ltd., one of the world's largest Pharmaceutical Manufacturers; and its impact on its Global Business. The related study was done in the year 2011 and report was prepared then.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
Presentation by NEPAD Agency on the African Medicines Regulatory Harmonisation made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Trends in Global Medical Device OEM Strategies and Issues for the Medical Dev...Tony Freeman
Presented at the February, 2013 mdmX Conference, Manning Advisors' Tony Freeman reviews issues facing the largest medical device manufacturers and implications for their supply chain.
This presentation provides a comprehensive overview of the current pharmaceutical industry. It begins with a look at some of the changes facing the industry and then moves into a discussion on digital technology and its impact on pharmaceutical companies. From there, the deck explores two digital trends, mobile and eDetailing. The presentation wraps up with some examples of pharmaceutical companies their digital presence.
Introduction
Global Inventory Management Strategy
Development of strategy
Inventory stock maintenance- Regular, Safety and Anticipatory stock
Customer fulfillment
Role of warehousing
Efficiency
Resilience
Agile/Adaptability
Quality control
Supply chain Best practices
Supply chain challenges
A workshop presentation for Medical Affairs Strategic Summit West held in San Diego on September 23, 2019. The workshop covered the following learning objectives:
* Understand the factors involved in selecting and prioritizing indications
* Understand the importance of strategic market segmentation
* Understand how Medical Affairs can be involved in the process of new product planning
Pharma method development 2016 brochureSharen Wallis
Pharmaceutical Methods Validation is a global annual event. This Pharmaceutical Methods Validation, Dubai brings together scientists, entrepreneurs and researchers from around the world. This international Pharmaceutical Methods validation conference is a critical examination of various Pharmaceutical Methods Validation techniques available at present and the recent additions to it would enormously enrich our knowledge in understanding the current requirements of the global pharmaceutical industry.
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
Information Management In Pharmaceutical IndustryFrank Wang
Pharmaceutical Industry Information Management Opportunities and Challenges in Research, Development, Clinical, Sales, Marketing, Managed Markets, Manufacturing, Supply Chain and Distribution
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
Health Policy Supporting Innovation in Korean Medical Device Sector (July 11,...Sung Yoon Bae
Presented in the AMCHAM Healthcare Innovation Seminar, held in Seoul, Korea on July 11, 2012.
Title: Toward Better Health Policy Supporting Innovation in Korean Medical Device Sector
Date: July 11, 2012
Speaker, Sung Yoon Bae, Professor of Healthcare Management, Inje University, Busan, Korea
Global supply chain in ranbaxy paonta sahib manufacturing facilityAnkur Srivastava
This is a project report made by me on the Global Supply Chain Process of Ranbaxy Laboratories Ltd., one of the world's largest Pharmaceutical Manufacturers; and its impact on its Global Business. The related study was done in the year 2011 and report was prepared then.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
Presentation by NEPAD Agency on the African Medicines Regulatory Harmonisation made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Trends in Global Medical Device OEM Strategies and Issues for the Medical Dev...Tony Freeman
Presented at the February, 2013 mdmX Conference, Manning Advisors' Tony Freeman reviews issues facing the largest medical device manufacturers and implications for their supply chain.
This presentation provides a comprehensive overview of the current pharmaceutical industry. It begins with a look at some of the changes facing the industry and then moves into a discussion on digital technology and its impact on pharmaceutical companies. From there, the deck explores two digital trends, mobile and eDetailing. The presentation wraps up with some examples of pharmaceutical companies their digital presence.
Introduction
Global Inventory Management Strategy
Development of strategy
Inventory stock maintenance- Regular, Safety and Anticipatory stock
Customer fulfillment
Role of warehousing
Efficiency
Resilience
Agile/Adaptability
Quality control
Supply chain Best practices
Supply chain challenges
A workshop presentation for Medical Affairs Strategic Summit West held in San Diego on September 23, 2019. The workshop covered the following learning objectives:
* Understand the factors involved in selecting and prioritizing indications
* Understand the importance of strategic market segmentation
* Understand how Medical Affairs can be involved in the process of new product planning
Pharma method development 2016 brochureSharen Wallis
Pharmaceutical Methods Validation is a global annual event. This Pharmaceutical Methods Validation, Dubai brings together scientists, entrepreneurs and researchers from around the world. This international Pharmaceutical Methods validation conference is a critical examination of various Pharmaceutical Methods Validation techniques available at present and the recent additions to it would enormously enrich our knowledge in understanding the current requirements of the global pharmaceutical industry.
Blockchain technology and applications from a financial perspectiveTommaso Pellizzari
Blockchain iniatives and projects are part of UniCredit digital agenda, which aims at leveraging on new technologies to reshape the Group and create new business opportunities. Unicredit white paper gives a presentation of the technology and enlightens the blockchain opportunity for the financial industry.
Tracxn Startup Research — Life Sciences Landscape, October 2016Tracxn
There were 20+ acquisitions in this space in 2016; IBM’s $2.6B acquisition of Truven Analytics, and Affymetrix’s acquisition by Thermo Fisher Scientific for $1.6B were the largest M&A events for the sector this year.
Innovative Marketing Practices for Optimization in Selected Pharmaceutical In...iicecollege
Pharmaceutical Industry is regulated by the production, distribution, selling and the marketing of the products or services which directly or indirectly includes medical, diagnostic and healthcare.It is regulated by economical, political and administrative authority to manage at all levels. So, the industry is governed by both the public and private sector. Therefore innovation is done in various pharma stakeholder and is needed in chronic and acute therapeutic segment.
For more details please visit
www.iicecollege.com
New Product Planning in the Pharmaceutical IndustryAnthony Russell
Lecture presented in the Competitive Intelligence and Pricing course as part of the University of Southern California Master of Science in Healthcare Decision Analysis program. Presented on June 14, 2020 at USC via Zoom. The lectures gives an overview of what new product planning is in the pharmaceutical industry, what tools are used during new product evaluations, and the key elements of a new product business case. The lecture includes a couple of case studies to be worked on by the class.
Telehealth is a collection of means or methods for enhancing healthcare, health education delivery, and support using telecommunication technologies. Telehealth plays a vital role in improving healthcare services with technology.
Telehealth is a collection of means or methods for enhancing healthcare, health education delivery, and support using telecommunication technologies. Telehealth plays a vital role in improving healthcare services with technology.
This presentation provides overview about our offerings under the Market Intelligence Services category. It mainly shows what we have done and what we can do in terms of studying and assessing the opportunities in new markets / products.
Future Pharma Trends - Long-term opportunities tempered by short-term challengesscottosur
An overview of the key trends shaping the pharmaceutical industry today, and those that are set to play a central role in the future, as companies transition towards a new business model: Pharma 2.0.
Provides key strategies and trends shaping the future of the pharmaceutical industry. Examines the impact of the Obama administration on US healthcare, and the implications for Pharma. Assesses the implications of the current economic and financial situation on healthcare. Analyzes key growth drivers and resistors set to shape Pharma\'s future.
Contact me at sosur@datamonitor.com to learn more!
Vertical market expansion hc gleikin2013q4campaign
ALP_AMD without recording file
1. Action Learning Project
Market Potential in UAE for
AlphaMD Analytics Company
Global MBA
1
S P Jain School of Global Management
Bhumika Kataria
Jasleen Sethi
Kim Hongrak
4. 1.1
4
A note on study about the company
• AMD Analytics is a start-
up focused on providing
solutions to life sciences
by conducting custom m
arket research
High quality solution Global site Various projectLife science
• In operations since last
1 year and have offices
in US & India. They also
have presence in Cana
da & EU.
• The company provides h
igh quality solutions to cl
ients within life sciences
(pharma, medical device
, biopharma, diagnostics
and imaging).
• Executed projects for
various companies at
different stages of
growth.
• 20 member team right
now & growing.
Growing up
5. 1.2
5
Objective of study
• Detailed study of Pharmaceutical Sector in UAE
• Analyzing their current and unmet needs
• Proposing a market strategy to approach the right target market
7. 2.1
7
Study on Pharma Sector in UAE
• Local manufacturing
Pharma companies
- 8
• Most developed
Pharma sector
• Strong growth in tra
ding in Pharma sect
or
• Investments in Healt
hcare sector DHC a
nd DuBiotech projec
ts
• Strong healthcare
infrastructure
• Huge scope - medic
al tourism industry –
Dh 1billion revenue i
n 2015
• Increment in openin
g of pharmacies in g
rocery shops
• highest per-capita
expenditures in medicines
• Huge potential for growth
– changing lifestyle
• Increase in income and aw
areness of self-monitoring
devices
• No. of registered
pharma companies
- 2688
• Market Size - 53.8 AED
• Growth rate – 7.9%
8. 2.2 Generic challenges faced by pharmaceutical companies in UAE
Market highly
relies on
imports for
hi-tech
prescriptions
Local manufa
cturing
sector is
small
Focuses on
basic
medicines
Pace of
regional
innovation is
slower
Prevalence of
counterfeit
products
entering and
exiting from
UAE
8
9. 2.3 Ansoff matrix
9
AMD analytics company to enter new market with
existing services(pharmaceutical)
• Market Development
PESTEL
TOWS
Categorize business
10. 2.4 Ansoff matrix – PESTEL analysis
SocialEconomicPolitical
Healthcare is regulated at
both Federal and Emirate level
UAE is benefitting from the health r
elated free zones like DuBiotech
Both soft and hard infrastructure
are a challenge.
Increase by 3.3% ,GDP in 2012
Product life cycle cost has shortene
d and in-licensing, R&D & marketing
costs have risen
UAE have an open economy with a
high GDP per capita, more than 30.
000 US dollars (according to IMF (2
014))
Substantial annual trade surplus
UAE’s population from different cult
ural background .Thus, each group
has its own set of unique healthcar
e needs.
The increasing obesity amongst as
sociated health risks.
Public activism has also increased
through the harnessing of new soci
al networking technologies.
10
11. 2.4
EnvironmentalLegalTechnology
Create new business prospects in ter
ms of new therapy systems and serv
ice provisions.
Demand for customized treatments
have unleashed new opportunities.
Many pharmaceutical companies to
work in partnership with IT companie
s to improve electronic processing, in
crease efficiency, reduce costs, and
protect patient confidentiality.
Law No. 4 prohibits opening of medic
al stores and pharmaceutical factorie
s without license.
License applicants for pharmacy or
medical store can be only UAE natio
nals.
Imports and distribution of imported
pharmaceutical products can only be
done if they are registered with the
Ministry of Health.
Law contains various labelling requir
ements.
Environmental Impact Assessment (
EIA) program.
To minimize environmental impact &
to preserve the pre-existing natural
heritage.
State-of-the-art waste disposal facili
ties, to conserve and recycle water
and energy.
More than 60 events & campaigns t
o drive the message of sustainabilit
y to all sections of the community.
Ansoff matrix – PESTEL analysis
11
12. 2.5 Ansoff matrix – TOWS analysis of AlphaMD
TOWS
Threat
Weakness Strength
12
• Nominal amount to be paid as initial payment(20%)
• Fixed project pricing (not overcharging)
• Follow SLAs and mention KPIs in contracts.
• Experts in medical and pharma field
• Conduct project globally
• Positive outlook for Biotech, Pharma industry
• Increase attention of people on health
• Huge potential for growth in healthcare sector
• Increase in per-capita expenditures in medicine
• More than 50 numbers local and global consulting
firm in Mumbai
• Increasing cost of human capital
• Solely focus on pharma industry
Opportunity
14. 3.1
14
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5
• Identify SME Pharma
& Biotech firms based
in UAE.
• Parameter Identification
and preparation of
discussion guide
• Identifying the key para
meters for prioritized or
ganizations through in-
depth Interview
• Prioritize the list throug
h Decision matrix
• Identifying the critical
Needs and quality drivers
for these organizations by
taking in-depth interviews
with key stakeholders and
implementing CTQ
Trees model
• Assess the performance requi
rements for these organization
s that AMD can satisfy and pit
ch in UAE market.
Methodology
15. 3.2
15
STEP 1 - Identified 50 SME Pharma & Biotech firms based in UAE
16. 3.3
16
STEP 2 - Parameter Identification
1. Product Launch
2. Franchise model
3. Marketing activities
4. Business development
5. Payer Insights
6. Business Analytics
7. Competitive Intelligence
8. Market research
9. Channel and contracting
18. 3.5
18
STEP 3 - Qualitative Analysis through In-depth interviews
Interviewee 1 Interviewee 2 Interviewee 3
Name Mr. Rajendra H. Bhandari Mr. Benson Dr. Fayyaz Vakil
Title Advisor Director Business Unit Manager
Company Neopharma
Aras Medical Devices and
Equipment
Gulf Pharmaceuticals
Call +971565396926 +971504606805 +971507102311
Interview
• Details of interviewees
19. 3.5 STEP 3 - Qualitative Analysis through In-depth interviews
• Medical reps should
be efficient
to convince
doctors & physicians
• Overall Insights from the in-depth interviews
• Competitive
intelligence
is the most important
parameter
• product launch
activities,
market research,
channel & contracting
• For Medical Devices &
Equipment companies,
delivery time key factors
• For R&D companies,
product development &
selection based on
customers’ needs
19
20. 3.5 STEP 3 - Qualitative Analysis through In-depth interviews
• Consumer insights are
gained with the help
of IMS health and marketing
team (internal or external)
• Overall Insights from the in-depth interviews
• For medical devices
company type,
contracting is done
mainly for the maintenance
of the products
• IMS health is a popular
research agency
working for many
organizations
to provide them with
market data
• Ministry of Health is
sole regulatory
authority to govern the
systems & processes
of this sector
20
21. 3.6
21
STEP 4 – Decision matrix 1
Parameters Product
Launch
Franchise
model
Marketing
activities
Business
developme
nt
Payer
Insights
Business
Analytics
Competitive
Intelligence
Market
research
Channel &
contracting
Weighted
total
Weights.
Distribution
& trading
3 0 3 4 5 3 5 3 5
Marketing 5 3 5 3 5 3 5 4 5
Manufacturi
ng & R&D
5 3 3 3 3 3 4 4 5
Medical
Devices
3 0 4 3 3 3 5 5 3
24. 3.6
24
STEP 4 – Decision matrix 4
Parameters Product
Launch
Franchise
model
Marketing
activities
Business
developme
nt
Payer
Insights
Business
Analytics
Competitive
Intelligence
Market
research
Channel &
contracting
Weighted
total
Weights.
Distribution
& trading
45 40 179
Marketi
ng
45 40 207
Manufacturi
ng & R&D
36 40 180
Medical
Devices
45 30 166
25. 3.6
25
STEP 4 – Conclusion from decision matrix analysis
• Marketing pharmaceutical companies scores the highest and hence has the
highest scope.
• R&D and distribution and trading pharmaceutical companies have got the
next highest weighted score.
• Medical devices company type seem to prefer competitive intelligence and
market research activities.
• The most important parameters for almost all companies types are
Competitive Intelligence and Channel and Contracting.
27. 3.7
27
STEP 5 – CTQ Trees for Alpha MD
• Budget friendly
quality services
• Competitive
Intelligence
• Channel &
Contracting
• Market
Research
• Gather primary intelligence without internal bias
• Affectively aggregate primary and secondary info.
• Thorough & global view of competitive landscape
• Understand reform based needs of customers
• Implement value based pricing & contracting
• Differentiate by getting a product out of lowest
cost for clients
• Examine & synchronize activities with regulatory.
• Build relationships to assess needs of different
players.
• Determine specific take-away to capitalize on
short amount of time.
29. 4.1
29
Conclusion
• Competitive intelligence >> market research >> channel & contracting.
• Marketing pharma companies to focus highly on competitive intelligence data.
• The SME companies require to outsource only if the services are cheaper.
• The companies do not compromise on the quality at the same time.
30. 4.2
30
Recommendations
1. Provide high quality competitive intel
ligence with effective Street Combin
g
2. Budget friendly services owing to pri
ce-sensitive market
3. Efficient contracting → special show
er equipment companies→ help des
alination
4. Accelerate the usage of Ayurvedic &
Naturopathy in UAE
31. 4.2
31
Recommendations
6. Build relations with MOH of Dubai →
counterfeiting and sales without pres
cription
5. Promote medicines dealing with obe
sity, diabetes and heart-related disea
ses
7. Come up with Me Too Market strateg
ies for R&D pharmaceutical compani
es
32. 4.3
32
Limitations
• Revenue and Market Cap not disclosed for most SMEs as they are found to be
closed and smaller groups.
• Dubai Healthcare City and Dubai Healthcare Authority denied to disclose data for
any of the companies as it was against their privacy policies.
• Unavailability of responses from the potential SME clients.
• Insights based on limited in-depth interviews conducted from three industry experts.
• Quantitative(questionnaire) to be conducted is not available.
34. 34
5.1 Meeting log
• 07/05/2016 – 45 mins – Dr. Kaushik De
• 21/06/2016 – 20 mins – Dr. Kaushik De
• 04/07/2016 – 35 mins – Dr. Kaushik De
• 04/08/2016 – 5 mins – Dr. Kaushik De
• 14/06/2016 – 60 mins – Dr. Balakrishna Grandhi
• 21/06/2016 – 20 mins – Dr. Balakrishna Grandhi
• 03/07/2016 – 60 mins – Dr. Balakrishna Grandhi
• 21/07/2016 – 90 mins – Dr. Balakrishna Grandhi
• 03/07/2016 - 20 mins – Dr. Dhrupad Mathur
• 03/08/2016 - 15 mins – Dr. Dhrupad Mathur
Roughly 2month we work with amd company, and what we have done is to come up with marketing strategy to SME size phama company in UAE
01- from first chapter, let s discuss about what AMD company does and explain research objective
02 – understand UAE pharma sector and what sme phama faced, thing is we analyze the market situation with ansoff matrix
03 – let me discuss about how to analyze. What we done was qualitative analysis with framework like CTQ, decision matrix, we also done questionnaire but doesn’t get
any responses.
04 – let me explain recommendation and conclusion
What AMD company does provide commercial research and analytics services to the pharma companies, medical, biotech etc.
They have global office, Canada
So far they conducted various project & bod member are pharma experts
Let s come to objective.
What is research objective, first one is deep study on pharma sector in UAE.
Second thing is understand what SME pharma faced to expand market
Last thing is what marketing strategy is proper for them.
- UAE-Most developed Pharma sector in UAE
According to a recent study, UAE has the most developed Pharmaceutical market in the Middle-East.
- Strong growth in trading in Pharma sector
UAE market attracts lots of manufacturers and traders.
There has been a strong growth in the trade in the Pharmaceutical sector.
- Investments in Healthcare sector by Dubai Healthcare City and DuBiotech projects
The widening of Gulf Cooperation Council market integration and also introduction of the integrated healthcare insurance systems, there is a huge scope for the boom in the trading sector in the Pharmaceutical industry in the long-run.
Huge investments in healthcare sectors in the UAE region such as Dubai Healthcare City, DuBiotech projects, etc. are great opportunities for FDIs in healthcare sector.
- UAE has a strong healthcare infrastructure and highest per-capita expenditure in medicines.
- Huge scope - medical tourism industry can be tapped
There is a huge scope for the pharmaceutical industry as they can tap the medical tourism industry.
Dh1 billion in medical tourism revenues in 2015.
Dubai’s 26 hospitals, both private and government, received nearly 630,831 health tourists last year, of which 298,359 were foreigners who came from abroad, accounting for nearly 46 per cent of the total
- Increment in opening of pharmacies in grocery shops
Increment in the opening of pharmacies in grocery stores will boost the Over-The-Counter sales, which will make the manufacturers as well as traders realize their opportunity for growth.
- Huge potential for growth - changing lifestyle, reduced physical activity, increase in obesity and heart related diseases
This is on the back of several factors, including a growing population, mandatory health insurance and the growth of regional medical tourism, among others.
There is a huge potential for further growth in this sector as lifestyle of people is changing and is hugely influenced by the western lifestyle, hence increasing diseases like obesity.
As 80% of the residents in Dubai do not participate in any of the physical activities, therefore there is a huge scope for the pharmaceutical sector to concentrate and target obese and overweight residents in UAE.
Heart related diseases and diabetes are also areas where Pharmaceutical industry should concentrate more as these diseases are common and a huge area for growth.
- Increase in income and awareness of self-monitoring devices
Increase in the incomes and awareness leads to increment in the personal care, which will hence increase the sales of medical devices that help in monitoring the health like blood-sugar levels, heart-rate monitors, etc.. Pharmaceutical products in this area have huge scope for growth.
- No. of registered pharma companies in UAE - 2688
- Market Size - 53.8 AED
- Growth rate – 7.9%
- Local manufacturing Pharma companies – 8
Local production of medicines is done by eight companies in the UAE. These include Julphar, Neopharma, Globalpharma, Medpharma few to be named. Besides supplying the domestic market, they export a share of their products to Middle East and North Africa and South East Asian countries.
Local manufacturing sector is small
Focuses on basic medicines
Market highly relies on imports for hi-tech prescriptions
Pace of regional innovation is slower
Prevalence of counterfeit products entering and exiting from UAE
Local manufacturing sector is small
Focuses on basic medicines
Market highly relies on imports for hi-tech prescriptions
Pace of regional innovation is slower
Prevalence of counterfeit products entering and exiting from UAE
Let me discuss about research methodology.
First step, what s happening is we identify 50 numbers SME phama, biotech, medical device company UAE
From step 2, we identified parameters & prepared interview discussion guide and questionnaire
Next, step 3, what we did is we scoring parameter through indepth interview and through doing framework, CTQ, decision matrix we decided which parameter is the most important.
Finally we come up with marketing strategy and conclusion
These are the 9 parameters
It is based on existing services that AMD company provides
What we prepare was questionnaire and indepth telephonic interview but we don’t receive any responses from questionnaire.
We completed 3 indepth telephonic interview
Competitive intelligence is most important parameter, what it is how much you can know about competitors product service strategy.
Also, product launch activity, market research, channel & contracting activity also important parameter.
-Regarding medical device & equipment companies, delivery time is key factor
-Medical reps roles is very important here to impact their revenue, they need to properly trained to convince doctor & physicians
-Ministry of heath has powerful authority. they control most pharma system & process.
-IMS health is popular consulting agency for healthcare performance, that is one of competitors to AMD company.
-Medical device company type normally make a revenue from maintenance of product that they sell
-They get consulting from IMS and get consumer insights